nintedanib
Showing 1 - 25 of 81
Healthy Trial (BI 1015550, Nintedanib, Pirfenidone)
Not yet recruiting
- Healthy
- BI 1015550
- +2 more
- (no location specified)
Oct 2, 2023
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary
Not yet recruiting
- Idiopathic Pulmonary Fibrosis
- Nintedanib
- (no location specified)
May 15, 2023
Idiopathic Pulmonary Fibrosis Trial in Adelaide (taladegib, nintedanib)
Not yet recruiting
- Idiopathic Pulmonary Fibrosis
- taladegib
- nintedanib
-
Adelaide, South Australia, AustraliaResearch Site
Apr 5, 2023
Safety of Nintedanib in Real World in China
Not yet recruiting
- Pulmonary Fibrosis
- nintedanib
- pirfenidone
-
Beijing, ChinaChina-Japan Friendship Hospital
Jan 26, 2023
Healthy Subjects Trial in Glendale (Nintedanib, AZD5055)
Not yet recruiting
- Healthy Subjects
- Nintedanib
- AZD5055
-
Glendale, United KingdomResearch Site
Dec 1, 2022
Lymphangioleiomyomatosis Trial in Milan (Nintedanib)
Completed
- Lymphangioleiomyomatosis
- Nintedanib
-
Milan, ItalyPneumology unit
Sep 26, 2022
NSCLC, NSCLC, Nonsmall Cell Lung Cancer Trial in Saint Louis (Nintedanib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- Nintedanib
-
Saint Louis, MissouriWashington University School of Medicine
Jan 3, 2023
Novel Coronavirus-induced Lung Fibrosis Trial in Chandigarh (Pirfenidone, Nintedanib)
Active, not recruiting
- Novel Coronavirus-induced Lung Fibrosis
- Pirfenidone
- Nintedanib
-
Chandigarh, IndiaPostgraduate Institute of Medical Education and Research
Sep 30, 2022
Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Completed
- Idiopathic Pulmonary Fibrosis
- Nintedanib
-
Milton, MassachusettsMedicus Economics, LCC
Aug 8, 2022
Appendix Cancer Trial in Charlotte (nintedanib)
Terminated
- Appendix Cancer
- nintedanib
-
Charlotte, North CarolinaLevine Cancer Institute
Aug 5, 2022
Carcinoid Tumor, Metastatic Carcinoid Tumor, Neuroendocrine Tumor Trial in Buffalo, Columbus (Laboratory Biomarker Analysis,
Active, not recruiting
- Carcinoid Tumor
- +2 more
- Laboratory Biomarker Analysis
- +3 more
-
Buffalo, New York
- +1 more
Nov 8, 2022
Lung Diseases, Interstitial (in Pediatric Populations), Childhood Interstitial Lung Disease (chILD) Trial (nintedanib)
Temporarily not available
- Lung Diseases, Interstitial (in Pediatric Populations)
- Childhood Interstitial Lung Disease (chILD)
- nintedanib
- (no location specified)
Jan 9, 2023
Telangiectasia, Hereditary Hemorrhagic Trial in Lausanne (Nintedanib, Placebo)
Recruiting
- Telangiectasia, Hereditary Hemorrhagic
- Nintedanib
- Placebo
-
Lausanne, Vaud, SwitzerlandRespiratory medicine Department, Lausanne University Hospital
Jul 22, 2022
Cough and Dyspnoea in Nintedanib-treated Connective Tissue
Not yet recruiting
- Lung Diseases, Interstitial
- Nintedanib
- (no location specified)
Aug 15, 2022
Dose Reduction and Discontinuation With Anti-Fibrotic
Not yet recruiting
- Idiopathic Pulmonary Fibrosis
- Pirfenidone
- Nintedanib
-
Ridgefield, ConnecticutBoehringer Ingelheim
Mar 24, 2023
Myositis Associated Interstitial Lund Disease (MA-ILD) Trial in United States (Nintedanib, Placebo, Standard of Care)
Not yet recruiting
- Myositis Associated Interstitial Lund Disease (MA-ILD)
- Nintedanib
- +2 more
-
Los Angeles, California
- +14 more
Mar 22, 2023
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in
Not yet recruiting
- Lung Diseases, Interstitial
- Nintedanib
- (no location specified)
Aug 19, 2022
Lung Diseases, Interstitial Trial in China (nintedanib, Placebo)
Recruiting
- Lung Diseases, Interstitial
- nintedanib
- Placebo
-
Beijing, China
- +15 more
Jan 23, 2023
Idiopathic Pulmonary Fibrosis Trial in Shanghai (HEC585, Pirfenidone, Nintedanib)
Completed
- Idiopathic Pulmonary Fibrosis
- HEC585
- +2 more
-
Shanghai, ChinaShanghai Xuhui Central Hospital
May 12, 2022
Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO) Trial in Basel (Nintedanib)
Recruiting
- Bronchiolitis Obliterans Syndrome (BOS)
- Bronchiolitis Obliterans (BO)
- Nintedanib
-
Basel, Switzerland
- +1 more
May 4, 2022
Lung-transplant Recipients Trial in Suresnes (Nintedanib, Placebo)
Recruiting
- Lung-transplant Recipients
- Nintedanib
- Placebo
-
Suresnes, FranceFoch Hospital
May 2, 2022
Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease Trial in United States (Nintedanib, Placebo)
Recruiting
- Pulmonary Fibrosis
- +2 more
- Nintedanib
- Placebo
-
Phoenix, Arizona
- +7 more
Oct 9, 2022
Trends in Quality of Life in Idiopathic Pulmonary Fibrosis Under
Active, not recruiting
- Idiopathic Pulmonary Fibrosis
- Nintedanib
-
Alexandroupoli, Greece
- +9 more
Aug 22, 2022
Lung Diseases, Interstitial Trial in Belgium (nintedanib)
Available
- Lung Diseases, Interstitial
- nintedanib
-
Aalst, Belgium
- +13 more
Aug 8, 2022